Search research articles
Contact Us
Filters
Showing results (31-40 of 168) with videos related to
Page
of 17
Sort By:
Cancer Chemotherapy and Pharmacology
|
February 11, 2022
Adaptive dosing of sunitinib in a metastatic renal cell carcinoma patient: when in silico modeling helps to go quicker to the point
Florent Ferrer, Jonathan Chauvin, Jean-Laurent Deville, et al.
Cancer Chemotherapy and Pharmacology
|
March 24, 2016
Pharmacokinetics and pharmacogenetics of Gemcitabine as a mainstay in adult and pediatric oncology: an EORTC-PAMM perspective
Joseph Ciccolini, Cindy Serdjebi, Godefridus J Peters, et al.
Annales De Biologie Clinique
|
October 23, 2014
[Clinical application, limits and perspectives of pharmacogenetic and pharmacokinetic analysis of anticancer drugs]
Anne-Sophie Chantry, Sylvie Quaranta, Joseph Ciccolini, et al.
Methods in Molecular Medicine
|
December 6, 2003
Enzyme-prodrug systems: thymidine phosphorylase/5'-deoxy-5-fluorouridine
Alexandre Evrard, Joseph Ciccolini, Pierre Cuq, et al.
Pharmacoeconomics
|
September 10, 2025
Eco Friendly and Budget Smart: An Economic and Environmental Evaluation of Alternative PD-1 and PD-L1 Inhibitor Dosing Regimens
Leo Karlsson, Joseph Ciccolini, Rob Ter Heine, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
June 17, 2015
Improving efficacy of the combination between antiangiogenic and chemotherapy: Time for mathematical modeling support
Joseph Ciccolini, Sébastien Benzekry, Bruno Lacarelle, et al.
British Journal of Clinical Pharmacology
|
August 8, 2022
Renal impairment and DPD testing: Watch out for false-positive results!
Laure Carriat, Sylvie Quaranta, Caroline Solas, et al.
JCO Precision Oncology
|
January 20, 2022
Mechanistic Learning for Combinatorial Strategies With Immuno-oncology Drugs: Can Model-Informed Designs Help Investigators?
Joseph Ciccolini, Dominique Barbolosi, Nicolas André, et al.
Clinical Pharmacokinetics
|
March 7, 2016
Revisiting Dosing Regimen Using Pharmacokinetic/Pharmacodynamic Mathematical Modeling: Densification and Intensification of Combination Cancer Therapy
Christophe Meille, Dominique Barbolosi, Joseph Ciccolini, et al.
Critical Reviews in Oncology/Hematology
|
August 12, 2018
Pharmacokinetics variability: Why nanoparticles are not just magic-bullets in oncology
Anne Rodallec, Sebastien Benzekry, Bruno Lacarelle, et al.
Page
of 17
Search research articles
Search
Showing results (31-40 of 168) with videos related to
Sort By:
Page
of 17
Cancer Chemotherapy and Pharmacology
|
February 11, 2022
Adaptive dosing of sunitinib in a metastatic renal cell carcinoma patient: when in silico modeling helps to go quicker to the point
Florent Ferrer, Jonathan Chauvin, Jean-Laurent Deville, et al.
Cancer Chemotherapy and Pharmacology
|
March 24, 2016
Pharmacokinetics and pharmacogenetics of Gemcitabine as a mainstay in adult and pediatric oncology: an EORTC-PAMM perspective
Joseph Ciccolini, Cindy Serdjebi, Godefridus J Peters, et al.
Annales De Biologie Clinique
|
October 23, 2014
[Clinical application, limits and perspectives of pharmacogenetic and pharmacokinetic analysis of anticancer drugs]
Anne-Sophie Chantry, Sylvie Quaranta, Joseph Ciccolini, et al.
Methods in Molecular Medicine
|
December 6, 2003
Enzyme-prodrug systems: thymidine phosphorylase/5'-deoxy-5-fluorouridine
Alexandre Evrard, Joseph Ciccolini, Pierre Cuq, et al.
Pharmacoeconomics
|
September 10, 2025
Eco Friendly and Budget Smart: An Economic and Environmental Evaluation of Alternative PD-1 and PD-L1 Inhibitor Dosing Regimens
Leo Karlsson, Joseph Ciccolini, Rob Ter Heine, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
June 17, 2015
Improving efficacy of the combination between antiangiogenic and chemotherapy: Time for mathematical modeling support
Joseph Ciccolini, Sébastien Benzekry, Bruno Lacarelle, et al.
British Journal of Clinical Pharmacology
|
August 8, 2022
Renal impairment and DPD testing: Watch out for false-positive results!
Laure Carriat, Sylvie Quaranta, Caroline Solas, et al.
JCO Precision Oncology
|
January 20, 2022
Mechanistic Learning for Combinatorial Strategies With Immuno-oncology Drugs: Can Model-Informed Designs Help Investigators?
Joseph Ciccolini, Dominique Barbolosi, Nicolas André, et al.
Clinical Pharmacokinetics
|
March 7, 2016
Revisiting Dosing Regimen Using Pharmacokinetic/Pharmacodynamic Mathematical Modeling: Densification and Intensification of Combination Cancer Therapy
Christophe Meille, Dominique Barbolosi, Joseph Ciccolini, et al.
Critical Reviews in Oncology/Hematology
|
August 12, 2018
Pharmacokinetics variability: Why nanoparticles are not just magic-bullets in oncology
Anne Rodallec, Sebastien Benzekry, Bruno Lacarelle, et al.
Page
of 17